Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.0010.002710%
Serotonin syndrome12.03.01.041; 15.05.04.016; 17.05.02.0040.001084%-
Sinus bradycardia02.03.03.0090.002168%
Skin cancer16.03.02.002; 23.08.02.0020.000542%-
Skin disorder23.03.03.0070.001084%-
Skin exfoliation23.03.07.0030.001192%-
Skin irritation23.03.04.0090.004878%-
Skin reaction10.01.03.019; 23.03.03.0130.002276%-
Sleep apnoea syndrome17.15.05.001; 19.02.05.002; 22.02.01.0130.000542%
Sleep disorder19.02.04.0010.001355%-
Somnolence17.02.04.006; 19.02.05.0030.007750%
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.0270.004878%-
Status epilepticus17.12.03.0050.000542%-
Subarachnoid haemorrhage12.01.10.011; 17.08.01.010; 24.07.04.0040.000542%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.006775%
Tachycardia02.03.02.007---
Tachypnoea22.02.01.0140.001355%-
Tension19.06.02.0050.000813%-
Thinking abnormal17.02.05.023; 19.10.03.0010.002927%-
Thyroid disorder05.02.01.002---
Tinnitus04.04.01.002; 17.04.07.0040.001843%
Transient ischaemic attack17.08.04.001; 24.04.06.0050.001084%
Tremor17.01.06.0020.005907%
Trigeminal neuralgia17.04.08.001---
Unresponsive to stimuli17.02.05.0310.000813%-
Urinary incontinence17.05.01.008; 20.02.02.0100.000813%
Urinary retention20.02.02.0110.001084%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular tachycardia02.03.04.010--
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene